Another masterful announcement by Recce that says nothing of substance. No new information or data on the efficacy of the topical trial. The two endpoints mentioned are:
1. 'To evaluate the efficacy of Recce 327 topical gel on ABSSSI.' 2. 'To evaluate the potential systemic bioavailability of single and multiple doses of Recce 327 topical gel applied once daily for 7 to 14 days to infected ABSSSI.'
These are not proper phase 2 trial endpoints and offer no qualitative value. Even if we accept these, the release also says that 93% of patients met A endpoint. This could mean that 93% of patients were not remotely cured or helped but showed 'bioavailability' (endpoint 2).
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)